NuCana PLC
NASDAQ:NCNA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
NuCana PLC
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
